Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yinghua, Liu, Yujie, Zhang, Chao, Chu, Junjun, Wu, Yanqing, Li, Yudong, Liu, Jieqiong, Li, Qian, Li, Shunying, Shi, Qianfeng, Jin, Liang, Zhao, Jianli, Yin, Dong, Efroni, Sol, Su, Fengxi, Yao, Herui, Song, Erwei, Liu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913295/
https://www.ncbi.nlm.nih.gov/pubmed/29686231
http://dx.doi.org/10.1038/s41467-018-03951-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913295/
https://www.ncbi.nlm.nih.gov/pubmed/29686231
http://dx.doi.org/10.1038/s41467-018-03951-0

Ejemplares similares